Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMOP with or without rituximab in elderly untreated aggressive non-Hodgkin lymphoma
ChiCTR2300078813Phase 2Not yet recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: objective response rate. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
mitoxantrone
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR2300078813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078813.